Core Viewpoint - Zhongke Borui (Beijing) Technology Co., Ltd. has completed a multi-million yuan Series B financing to enhance its brain-computer interface (BCI) technology and clinical applications, aligning with national development strategies for the industry [2][9]. Group 1: Company Overview - Zhongke Borui was established in 2017 and focuses on the transformation and industrialization of BCI technology, emphasizing practical clinical applications rather than conceptual development [4]. - The company collaborates with top medical institutions, such as Capital Medical University Xuanwu Hospital and Tiantan Hospital, to address critical clinical needs in areas like perioperative intensive care and stroke rehabilitation [5]. Group 2: Product Development and Innovation - Zhongke Borui has developed a comprehensive product line that integrates BCI technology with artificial intelligence, covering the entire chain from research and development to clinical application [5][7]. - The company has created innovative products, including the world's only non-invasive multi-channel brain oxygen monitor and a photonic synchronous brain function imaging device, which significantly enhance surgical outcomes in functional neurosurgery [5][7]. Group 3: Strategic Goals and Future Plans - The company aims to establish a full-cycle BCI medical ecosystem that includes diagnosis, monitoring, treatment, and rehabilitation, focusing on brain health [9]. - Following the recent financing, Zhongke Borui plans to increase investment in core technology research, enhance its intellectual property portfolio, and expand production capacity to support market growth [9].